Osborne, R., Filiaci, V., Schink, J., et al. (2008) A Randomized Phase III Trial Comparing Weekly Parenteral Methotrexate and “Pulsed” Dactinomycin as Primary Management for Low Risk Gestational Trophoblastic Neoplasia: A Gynecologic Oncology Group Study. Gynecologic Oncology, 108, S2-S31.

has been cited by the following article:

• TITLE: Efficacy and Risk Factors Associated to Resistance to Single-Agent Chemotherapy in Low-Risk Gestational Trophoblastic Neoplasia

  AUTHORS: Mamour Gueye, Mame Diarra Ndiaye-Gueye, Serigne Modou Kane-Gueye, Fatou Niass Dia, Aissatou Thiam, Sr. Elisabeth Diouf, Jean Charles Moreau

  KEYWORDS: Gestational Trophoblastic Neoplasia, Chemotherapy, International Federation of Gynecology and Obstetrics, Resistance

  JOURNAL NAME: Open Journal of Obstetrics and Gynecology, Vol.6 No.1, January 21, 2016

  ABSTRACT: Objectives: This study aimed to assess efficacy of intramuscular methotrexate 8-day protocol in the treatment of low-risk gestational trophoblastic neoplasia and also identify prognostic factors associated with treatment failure, necessitating second line chemotherapy. Methods: This study was performed at Gynaecologic and Obstetric Clinic of Dakar Teaching Hospital, the reference Centre of Gestational Trophoblastic Disease in Senegal. At the beginning of 2011, patients were followed according to FIGO’s recommendations. From 2011 to 2014, we diagnosed 88 low-risk gestational trophoblastic neoplasia (GTN) patients (WHO score